Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Biddi... (erred provider agreement with Apria Heal...)

HOME >> MEDICINE >> NEWS

Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process

Date:6/2/2008

erred provider agreement with Apria Healthcare, Inc. (NYSE: AHG), America's leading provider of integrated home healthcare products and services. Apria was awarded contracts to provide NPWT to beneficiaries in seven of the ten designated competitive bidding areas included in the first phase of the CMS competitive bidding program. With approximately 550 locations throughout the U.S., Apria serves over 2 million patients annually. The Apria/Smith & Nephew collaboration will provide a smooth transition from hospital to homecare, giving more patients access to clinically effective NPWT while reducing overall treatment costs. In addition to Apria being awarded contracts, Smith & Nephew NPWT systems will be available through existing regional providers in two further competitive bidding areas.

In addition, Smith & Nephew has been working in collaboration with Universal Hospital Services, Inc. (UHS) since October 2007, providing NPWT to the U.S. acute care and long-term care markets. The continuum of care is completed, through UHS focusing on acute care and LTACs, and Apria, along with our existing regional providers, providing NPWT to home patients upon hospital discharge.

As a global leader in wound care, Smith & Nephew is unique in that it offers a total wound management solution that includes NPWT and a comprehensive portfolio of advanced wound management products from ACTICOAT(TM) and ALLEVYN(TM) to VERSAJET(TM), along with service and education to help ensure that the right products are used at the right time on the right wounds. In addition to being FDA-cleared in the U.S., the Smith & Nephew NPWT systems are cleared for sale in Australia, Canada and South Africa as well as CE-marked for use in Europe.

For more information ab
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
2. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
3. Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
4. GlaxoSmithKline Announces $500,000 in Fellowships at Stanford Graduate School of Business
5. SmithAmundsen Elects New Partner, Linda F. Newman
6. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.
7. IADR and GlaxoSmithKline Consumer Healthcare announce winners
8. A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
9. Smith & Nephew Endoscopy Launches the FOOTPRINT PK Suture Anchor for Shoulder Repair
10. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
11. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.

Post Your Comments:

Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Biddi...(erred provider agreement with Apria Heal...),Health